Advertisement

Application of Unnatural Amino Acids to the De Novo Design of Selective Antibiotic Peptides

  • Rickey P. HicksEmail author
  • Amanda L. Russell
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 794)

Abstract

Because of their unique mechanism of cytotoxicity against bacteria and other microorganisms, antimicrobial peptides have received a great deal of attention as possible therapeutic agents. Incorporation of unnatural amino acids into the peptide sequences has the potential to improve the organism selectivity and potency of these peptides as well as increase their metabolic stability. This protocol outlines the logic used to selectively incorporate unnatural amino acid into a peptide sequence in an attempt to obtain peptides with increased therapeutic potential as antibiotic agents.

Key words

Antimicrobial peptides Unnatural amino acids Organism selectivity De novo 

Notes

Acknowledgements

The authors would like to acknowledge funding from the Bacterial Therapeutics Program 2.1 of the Defense Threat Reduction Agency, contract # W81XWH-08-2-0095. The authors would also like to acknowledge funding from the North Carolina Biotechnology Center grant number 2006-FRG-1015 and from East Carolina University.

References

  1. 1.
    Ma J S (2003) Unnatural amino acids in drug discovery. CHIMICA OGGI Chemistry Today, June, 65–68.Google Scholar
  2. 2.
    Hendrickson T L, de Crecy-Lagard V, Schimmel P (2004) Incorporation of nonnatural amino acids into proteins. Annu Rev Biochem 73, 147–176.PubMedCrossRefGoogle Scholar
  3. 3.
    Padgett C L. et al. (2007) Unnatural amino acid mutagenesis of GABAa receptor binding site residues reveals a novel cation-pie interaction between GABA and b2 Tyr97. J Neurosci 27, 886–892.PubMedCrossRefGoogle Scholar
  4. 4.
    Rodriquez E A, Lester H A, Dougherty D A (2006) In vivo incorporation of multiple unnatual amino acids through nonsense and frame shift suppression. PNAS 103, 8650–8655.CrossRefGoogle Scholar
  5. 5.
    Yeaman M R, Yount N Y (2003) Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 55, 27–55.PubMedCrossRefGoogle Scholar
  6. 6.
    Dennison S R et al. (2005) Amphiphilic α-helical antimicrobial peptides and their structure/function relationships. Prot Pept Lett 12, 31–39.CrossRefGoogle Scholar
  7. 7.
    Ganz T (2003) Defensins: antimicrobial peptides of innate immunity. Nature Reviews, Immun 3, 710–720.CrossRefGoogle Scholar
  8. 8.
    Simmaco M, Mignogna G, Barra D (1999) Antimicrobial peptides from amphibian skin: what do they tell us? Biopolymers 47, 435–450.CrossRefGoogle Scholar
  9. 9.
    Lee D G, et al. (2004) Structure-antiviral activity relationships of cecropin A-magainin 2 hybrid peptide and its analogues. J Pept Sci 10, 298–303.PubMedCrossRefGoogle Scholar
  10. 10.
    Patch J A, Barron A E (2003) Helical peptoid mimics of magainin-2 amide. J Am Chem Soc 125, 12092–12093.PubMedCrossRefGoogle Scholar
  11. 11.
    Jasir A et al. (2003) New antimicrobial cystatin C-based peptide active against gram-positive bacterial pathogens, including methicillin-resistant Staphylococcus aureus and multiresistant coagulase-negative staphylococci. APMIS 111, 1004–1010.PubMedCrossRefGoogle Scholar
  12. 12.
    Deslouches B et al. (2005) Activity of the De Novo engineered antimicrobial peptide WLBU2 against pseudomonas aeruginosa in human serum and whole blood for systemic applications. Antimicro Agents Chemother 49, 3208–3216.CrossRefGoogle Scholar
  13. 13.
    Conlon J M, Abraham B, Leprince J (2007) Strategies for transformation of naturally-occurring amphibian antimicrobial peptides into therapeutically valuable anti-infective agents. Methods 42, 349–357.PubMedCrossRefGoogle Scholar
  14. 14.
    Shlaes D M, Projan S J, Edwards J E (2004) Antibiotic discovery: state of the state. ASM News 70, 275–281.Google Scholar
  15. 15.
    Wang G, Li X, Wang Z (2009) APD2: the updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Res. 37, 933–937.CrossRefGoogle Scholar
  16. 16.
    Khandelia H I, Mouritsen O G (2008) The impact of peptides on lipid membranes. Biochim Biophys Acta 1778, 1528–1536.PubMedCrossRefGoogle Scholar
  17. 17.
    Hancock R E W, Lehrer R (1998) Cationic peptides: a new source of antibiotics. Trends Biotechnol 16, 82–88.PubMedCrossRefGoogle Scholar
  18. 18.
    Toke O (2005) Antimicrobial peptides; new candidates in the fight against bacterial infections. Biopolymers 80, 717–735.PubMedCrossRefGoogle Scholar
  19. 19.
    Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415, 389–395.PubMedCrossRefGoogle Scholar
  20. 20.
    Powers J-P S, Hancock R E W (2003) The relationship between peptide structure and antibacterial activity. Peptides 24, 1681–1691.PubMedCrossRefGoogle Scholar
  21. 21.
    Brogden K A (2005) Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nature Reviews Microbiol 3, 238–250.CrossRefGoogle Scholar
  22. 22.
    Hicks R P et al. (2003) Comparison of the conformation and electrostatic surface properties of magainin peptides bound to SDS and DPC micelles: Insight into possible modes on antimicrobial activity. Biopolymers 68, 459–470.PubMedCrossRefGoogle Scholar
  23. 23.
    Song Y M et al. (2005) Cell selectivity and mechanism of action of antimicrobial model peptides containing peptoid residues. Biochemistry 44, 12094–12106.PubMedCrossRefGoogle Scholar
  24. 24.
    Papo N, Shai Y (2004) Effects of drastic sequence alteration and D-amino acid incorporation on the membrane binding behavior of lytic peptides. Biochemistry 43, 6393–6403.PubMedCrossRefGoogle Scholar
  25. 25.
    Dathe M et al. (2002) General aspects of peptide selectivity towards lipid bilayers and cell membrane studied by variation of structural parameters of amphipathic α-helical model peptides. Biochim Biophys Acta 1558, 171–186.PubMedCrossRefGoogle Scholar
  26. 26.
    Chen Y et al. (2005) Rational design of α-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index. J Biol Chem 280, 12316–12329.PubMedCrossRefGoogle Scholar
  27. 27.
    Oren Z, Hong J, Shai Y (1997) A repertoire of novel antibacterial diastereomeric peptides with selective cytolytic activity. J Biol Chem 272, 14643–14649.PubMedCrossRefGoogle Scholar
  28. 28.
    Dathe M, Wiencek J M (1999) Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells. Biochim Biophys Acta 1462, 71–87.PubMedCrossRefGoogle Scholar
  29. 29.
    Papo N, Shai Y (2003) New lytic peptides based on the D,L amphipathic helix motif preferentially kill tumor cells compared to normal cells. Biochemistry 42, 9346–9354.PubMedCrossRefGoogle Scholar
  30. 30.
    Giangaspero A, Sandri L, Tossi A (2001) Amphipathic α-helical antimicrobial peptides. Eur J Biochem 268, 5589–5600.PubMedCrossRefGoogle Scholar
  31. 31.
    Azuma I et al. (1973) Cell wall of Mycobacterium lepraemurium strain Hawaii. J Bacteriology 113, 515–518.Google Scholar
  32. 32.
    Yeaman N R, Yount N Y (2003) Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 55, 27–55.PubMedCrossRefGoogle Scholar
  33. 33.
    Glukhov E et al. (2005) Basis for selectivity of cationic antimicrobial peptides for bacterial versus mammalian membranes. J Biol Chem 280, 33960–33967.PubMedCrossRefGoogle Scholar
  34. 34.
    Zhang L, Harris S C, Falla T J (2005) Therapeutic application of innate immunity peptides. Horizon Bioscience, San Diego.Google Scholar
  35. 35.
    Bush K (2004) Why it is important to continue antibacterial drug discovery. ASM News 70, 282–287.Google Scholar
  36. 36.
    Klevens R M et al. (2007) Estimating health care-associated infections and deaths in U.S. hospitals.2002. Public Health Reports 122, 160–166.PubMedGoogle Scholar
  37. 37.
    Wang G L X, Wang Z ( 2009) APD2: the updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Res 37, D933–937.PubMedCrossRefGoogle Scholar
  38. 38.
    Hancock R E, Patrzykat A (2002) Clinical development of cationic antimicrobial peptides: from natural to novel antibiotics. Curr Drug Targets Infect Disord 2, 79–83.PubMedCrossRefGoogle Scholar
  39. 39.
    Kamysz W (2005) Are antimicrobial peptides an alternative for conventional antibiotics. Nuclear Med Reviews 8, 78–86.Google Scholar
  40. 40.
    Zhang L, Falla T J (2009) Host defense peptides for use as potential therapeutics. Curr Opin Investig Drugs 10, 164–171.PubMedGoogle Scholar
  41. 41.
    Nowick J S et al. (2000) An unnatural amino acid that mimics a tripeptide β-strand and forms β-sheet like hydrogen-bonded dimers. J Am Chem Soc 122, 7654–7661.CrossRefGoogle Scholar
  42. 42.
    Nowick J S (2008) Exploring β-sheet structure and interactions with chemical model systems. Acc Chem Res 41, 1319–1330.PubMedCrossRefGoogle Scholar
  43. 43.
    Grauer A A, Konig B (2009) Synthesis of new Cα tetrasubstituted α-amino acids. Beilstein J Org Chem 5, 5.PubMedCrossRefGoogle Scholar
  44. 44.
    Kyle D J et al. (1993) NMR and computational evidence that high-affinity bradykinin receptor antagonists adopt C-terminal beta-turns. J Med Chem 36, 1450–1460.PubMedCrossRefGoogle Scholar
  45. 45.
    Kyle D J et al. (1992) A novel beta-turn mimic useful for mapping the unknown topology of peptide receptors. Pept Res 5, 206–209.PubMedGoogle Scholar
  46. 46.
    Oh J E, Lee K H (1999) Synthesis of novel unnatural amino acid as a building block and its incorporation into an antimicrobial peptide. Bioorg & Med Chem 7, 2985–2990.CrossRefGoogle Scholar
  47. 47.
    Bhonsle J B et al. (2007) Application of 3D-QSAR for identification of descriptors defining bioactivity of antimicrobial peptides. J Med Chem 50, 6545-–6553.PubMedCrossRefGoogle Scholar
  48. 48.
    Haug B E, Strom M B, Svendsen J S M (2007) The medicinal chemistry of short lactoferricin-based antibacterial peptides. Curr Med Chem 14, 1–18.PubMedCrossRefGoogle Scholar
  49. 49.
    Venugopal D et al. (2010) Novel antimicrobial peptides that exhibit activity against select agents and other drug resistant bacteria. Bioorg & Med Chem 18, 5137–5147.CrossRefGoogle Scholar
  50. 50.
    Hicks R P et al. (2007) De Novo design of selective antibiotic peptides by incorporation of un-natural amino acids. J Med Chem 50, 3026–3036.PubMedCrossRefGoogle Scholar
  51. 51.
    Matsuzaki K. (1998) Magainins as paradigm for the mode of action of pore forming polypeptides. Biochim Biophys Acta 1376, 391–400.PubMedGoogle Scholar
  52. 52.
    Wenk M R, Seelig J (1998) Magainin 2 amide interaction with lipid membranes: calorimetric detection of peptide binding and pore formation. Biochemistry 37, 3909–3916.PubMedCrossRefGoogle Scholar
  53. 53.
    Yang L et al. (2000) Crystallization of antimicrobial pores in membranes: magainin and protegrin. Biochemical J 79, 2002–2009.Google Scholar
  54. 54.
    Jing W et al. (2003) The structure of the antimicrobial peptide Ac-RRWWRF-NH2 bound to micelles and its interactions with phospholipid bilayers. J Pept Res 61, 219–229.PubMedCrossRefGoogle Scholar
  55. 55.
    Watson R M et al. (2001) Conformational changes in pediocin AcH upon vesicle binding and approximation of the membrane-bound structure in detergent micelles. Biochemistry 40, 14037–14046.PubMedCrossRefGoogle Scholar
  56. 56.
    Whitehead T L et al. (1998) Membrane-induced secondary structures of neuropeptides: a comparison of the solution conformations adopted by agonists and antagonists of the mammalian tachykinin NK1 receptor. J Med Chem 41, 1497–1506.PubMedCrossRefGoogle Scholar
  57. 57.
    Whitehead T L, Hicks R P (2001) Rationale for using simple and complex micelles in polypeptide conformational analysis. Recent Res Devel Med Chem 1, 213–233.Google Scholar
  58. 58.
    Perrine S A et al. (2000) Solution structures in SDS micelles and functional activity at the bullfrog substance P receptor of ranatachykinin peptides. J Med Chem 43, 1741–1753.PubMedCrossRefGoogle Scholar
  59. 59.
    Young J K, Hicks R P (1994) NMR and molecular modeling investigations of the neuropeptide bradykinin in three different solvent systems: DMSO, 9:1 dioxane/water, and in the presence of 7.4 mM lysophosphatidylcholine micelles. Biopolymers 34, 611–623.PubMedCrossRefGoogle Scholar
  60. 60.
    Russell A L et al. (2010) Spectroscopic and thermodynamic evidence for antimicrobial peptide membrane selectivity. Chem Phys Lipids 163, 488–497.PubMedCrossRefGoogle Scholar
  61. 61.
    Porter E A, Weisblum B, Gellman S H (2002) Mimicry of host defense peptides by unnatural oligomers: antimicrobial β-peptides. J Am Chem Soc 124, 7324–7330.PubMedCrossRefGoogle Scholar
  62. 62.
    Tossi A, Sandri L, Glangaspero A. (2000) Amphipathic α-helical antimicrobial peptides. Biopolymers 55, 4–30.PubMedCrossRefGoogle Scholar
  63. 63.
    Vasudev P G et al. (2010) Structural chemistry of peptides containing backbone expanded amino acid residues: Conformational features of β, ε and hybrid peptides. Chem Reviews 111, 657–687.Google Scholar
  64. 64.
    Turner J et al. (1998) Activites of LL-37, a cathelin-associated antimicrobial peptide of human neutrophilis. Antimicr Agents Chemother 42, 2206–2214.Google Scholar
  65. 65.
    Fuchs P F J et al. (2006) Kinetics and thermodynamics of type VIII β-turn formation: A CD, NMR and microsecond explicit molecular dynamics study of the GDNP tetrapeptide. Biophysical J 90, 2745–2759.CrossRefGoogle Scholar
  66. 66.
    Perczel A, Fasman G D (1992) Quantitative analysis of cyclic β-turn models, Prot Sci 1, 378–395.CrossRefGoogle Scholar
  67. 67.
    Crisma M et al. (2005) Turn stabilization in short peptides by Cα-methylated α-amino acids. Biopolymers 80, 279–293.PubMedCrossRefGoogle Scholar
  68. 68.
    Toniolo C et al. (2002) Control of peptide conformation by the Thorpe-Ingold effect (Cα-tetrasubstitution). Pept Sci 60, 396–419.Google Scholar
  69. 69.
    Epand R F et al. (2004) Antimicrobial 14-helical β-peptides: Potent bilayer disrupting agents. Biochemistry 43, 9527–9535.PubMedCrossRefGoogle Scholar
  70. 70.
    Seebach D, Matthews J L (1997) β-Peptides: a surprise at every turn. Chem Commun 2015–2022.Google Scholar
  71. 71.
    White S H, Wimley W C (1998) Hydrophobic interactions of peptides with membrane interfaces. Biochim Biophys Acta 1376, 339–352.PubMedGoogle Scholar
  72. 72.
    Wimley W C, White S H (1993) Membrane partitioning: distinguishing bilayer effects from hydrophobic effect. Biochemistry 32, 6307–6312.PubMedCrossRefGoogle Scholar
  73. 73.
    Dathe M et al. (1997) Hydrophobicity, hydrophobic moment and angle subtended by charged residues modulate antibacterial and haemolytic activity of amphipathic helical peptides. FEBS Letter 403, 208–213.CrossRefGoogle Scholar
  74. 74.
    Kiyota T, Lee S, Suqihara G (1996) Design and synthesis of amphiphilic alpha-helical model peptides with systematically varied hydrophobic–hydrophilic balance and their interaction with lipid- and bio-membranes. Biochemistry 35, 13196–13201.PubMedCrossRefGoogle Scholar
  75. 75.
    Medina M L et al. (2002) Transient vesicle leakage initiated by synthetic apoptotic peptides derived from the death domain of neurotrophin receptor p75NTR. J Pept Sci 59, 149–158.Google Scholar
  76. 76.
    Wei S-T (2006) Solution structure of a novel tryptophan-rich peptide with bidirectional antimicrobial activity. J Bacteriology 188, 328–334.CrossRefGoogle Scholar
  77. 77.
    Hunter H N et al. (2005) The interactions of antimicrobial peptides derived from lysozyme with model membrane systems. Biochim Biophys Acta, 1668, 175–189.PubMedCrossRefGoogle Scholar
  78. 78.
    Wieprecht T et al. (2000) Membrane binding and pore formation of the antibacterial peptide PGLa: thermodynamic and mechanistic aspects. Biochemistry 39, 442–452.PubMedCrossRefGoogle Scholar
  79. 79.
    Wieprecht T, Apostolov O, Seelig J (2000) Binding of the antibacterial peptide magainin 2 amide to small and large unilamellar vesicles. Biophys Chem 85, 187–198.PubMedCrossRefGoogle Scholar
  80. 80.
    Wieprecht T, Beyermann M, Seelig J (2002) Thermodynamics of the coil α-helix transition of amphipathic peptides in a membrane environment: role of vesicle curvature. Biophys Chem 96, 191–201.PubMedCrossRefGoogle Scholar
  81. 81.
    Wieprecht T, Seelig J (2002) Isothermal titration calorimetry for studying interactions between peptides and lipid membranes. In: Simon S A, McIntosh T J (eds), Peptide–Lipid Interactions, Academic Press, San Diego, pp 32–58.Google Scholar
  82. 82.
    Wen S (2007) Dicynthaurin (ala) monomer interaction with phospholipid bilayers studied by fluorescence leakages and isothermal titration calorimetry. J Phys Chem 111, 6280–6287.CrossRefGoogle Scholar
  83. 83.
    Bringezu F et al. (2007) The insertion of the antimicrobial peptide dicynthaurin monomer in model membranes: thermodynamic and structural characterization. Biochemistry 46, 5678–5686.PubMedCrossRefGoogle Scholar
  84. 84.
    Wieprecht T et al. (1996) Conformation and functional study of magainin 2 in model membrane environment using the new approach of systematic double D-amino acid replacement. Biochemistry 35, 10844–10853.PubMedCrossRefGoogle Scholar
  85. 85.
    Dathe M (1996) Peptide helicity and membrane surface charge modulate the balance of electrostatic and hydrophobic interactions with lipid bilayers and biological membranes. Biochemistry 35, 12612–12622.PubMedCrossRefGoogle Scholar
  86. 86.
    Tamba Y, Yamazaki M (2005) Single giant unilamellar vesicle method reveals effect of antimicrobial peptide Magainin 2 on membrane permeability. Biochemistry 44, 15823–15833.PubMedCrossRefGoogle Scholar
  87. 87.
    Mahe E et al. (1998) Solid-phase synthesis, conformational analysis, and biological activity of AVR9 elicitor peptides of the fungal tomato pathogen Cladosporium fulvum. J Pept Res 52, 482–494.PubMedCrossRefGoogle Scholar
  88. 88.
    Muri E M et al. (2004) N-t-Boc-amino acid esters of isomannide potential inhibitors of serine proteases. Amino Acids 27, 153–159.PubMedCrossRefGoogle Scholar
  89. 89.
    Grant G A (2002) Synthetic Peptides, A user’s guide, 2nd ed., Oxford University Press, New York, NY.Google Scholar
  90. 90.
    Birr C, Lochinger W, Wieland T (1969) Peptide synthesis. XLII. Comparison of several coupling methods. Justus Liebigs Annalen der Chemie 729, 213–216.Google Scholar
  91. 91.
    Bodanszky M (1985) In search of new methods in peptide synthesis. A review of the last three decades. Internat J Pep Prot Res 25, 449–474.Google Scholar
  92. 92.
    Benoiton N L (2006) Chemistry of Peptide Synthesis, Taylor and Francis (CRC Press), Boca-Raton, FL.Google Scholar
  93. 93.
    Gobbo M et al. (2002) Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. J Med Chem 45, 4494–4505.PubMedCrossRefGoogle Scholar
  94. 94.
    Whitehead T L, Jones L M, Hicks R P (2001) Effects of the incorporation of CHAPS into SDS micelles on neuropeptide-micelle binding: separation of the role of electrostatic interactions from hydrophobic interactions. Biopolymers 58, 593–605.PubMedCrossRefGoogle Scholar
  95. 95.
    Whitehead T L, Jones L M, Hicks R P (2004) PFG-NMR investigations of the binding of cationic neuropeptides to anionic and zwitterionic micelles. J Biomol Struct Dyn 21, 567–576.PubMedGoogle Scholar
  96. 96.
    Vogel H J et al. (2002) Towards a structure–function analysis of bovine lactoferricin and related tryptophan- and arginine-containing peptides. Biochem Cell Bio 80, 49–63.CrossRefGoogle Scholar
  97. 97.
    Crisma M et al. (2007) Peptide α/310-helix dimorphism in the crystal state. J Am Chem Soc 129, 15471–15473.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of ChemistryEast Carolina UniversityGreenvilleUSA

Personalised recommendations